[1] Chapman & Hall/CRC Published on CD-ROM Hampden Data Services Ltd. 1999.
[2] Siddiqui, F.A.; Arayne, M.S.; Sultana, N.; Mirza, A.Z.; Qureshi, F.; Zuberi, M.H. Facile and manifest spectro-photometric methods for the determination of six quinolone antibiotics in pharmaceutical formulations using iron salts. Med. Chem. Res.2010, 19, 1259-1272.
[3] Rakhshinda, S.; Najma, S.; Khalid, M.K.; Nosheen, A.; Muhammad, A.; Saeed, A. Effects of skeletal modifications of ciprofloxacin on antibacterial, antifungal and cytotoxic activities, J. Chin. Clin. Med. 2007, 2, 188-195.
[4] Arayne, M.S.; Sultana, N.; Rizvi, S.B.S.; Haroon, U. In vitro drug interaction studies of atorvastatin with ciprofloxacin, gatifloxacin, and ofloxacin. Med. Chem. Res. 2010, 19, 717-731.
[5] Barriere, S.L.; Catlin, D.H.; Orlando, P.L; Noe. A.; Frost, R.W. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob. Agents Chemother. 1990, 34, 823-826.
[6] Avent, C.K.; Krinsky, D.; Kirklin, J.K.; Bourge, R.C.; Figg, W.D. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. Am. J. Med. 1988, 85, 452-454.
[7] Shafi, N.; Siddiqui, F.A.; Arayne, M.S.; Sultana, N. In-vitro drug-drug interaction studies of diltiazem with floroquinolones. J. Liq. Chromatogr. Relat. Technol. 2017, 40, 1003-1014.
[8] Arayne, M.S.; Sultana, N.; Hussain, F. Interactions between ciprofloxacin and antacids- dissolution and adsorption studies. Drug Metabol. Drug Interact. 2005, 21, 117-129.
[9] Najma, S.M.; Saeed, A.; Fida, H. In vitro Monitoring of Ciprofloxacin Antacids Interactions by UV & HPLC. Pakistan J. Pharm. Sci. 2005, 18, 23-31.
[10] Polk, R.E.; Healy, D.P.; Sahai, J.; Drawl, L.; Racht, E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob. Agent. Chemother. 1989, 33, 1841-1844.
[11] Ndagi, U.; Mhlongo, N.; Soliman, M.E. Metal complexes in cancer therapy-an update from drug design perspective. Drug Des. Devel. Ther. 2017, 11, 599-616.
[12] Bauer, A.W.; Kirby, W.M.M.; Sherris, J.C.; Turck, M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol. 1966, 45, 493-496.
[13] Victor, L.M.D. Antibiotics in Laboratory Medicine. Williams and Wilkins, 1991, 3, 17, 19 and 27.
[14] National Committee on Clinical Laboratory Standards, 2012, Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—11th Edition, M02-A11 Vol. 32 No. 1 Replaces M02-A10 Vol. 29 No. 1.
[15] Hartshorn, E.A.; Lomaestero, B.N.; Bailie, G.R. Quinolone-Cation Interactions: A Review. Ann. Pharm. 1991, 25, 1249-1258.
[16] Turel, I.; Leban, I.; Bukovec, N. Synthesis, characterization, and crystal structure of a copper(II) complex with quinolone family member (ciprofloxacin): bis(1)-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate) copper(II) chloride hexahydrate. J. Inorg. Biochem. 1994, 56, 273-282.
[17] Guanggun, W.U.; Guoping, W.; Xuchun, F.; Longguan, Z. Synthesis, Crystal Structure, Stacking Effect and Antibacterial Studies of a Novel Quaternary Copper (II) Complex with Quinolone. Molecule. 2003, 8, 287-296.
[18] Lecomte, S.; Baron, M.H.; Chenon, M.T.; Coupry, C.; Moreau, N.J. Effect of magnesium complexation by fluoroquinolones on their antibacterial properties. Antimicrob. Agent. Chemother. 1994, 38, 2810-2816.
[19] Marija, Z.; Iztok, T.; Peter, B.; Andrew, J.P.W.; David, J.W. Synthesis and Characterization of Two Novel Zinc(II) Complexes with Ciprofloxacin. Crystal Structure of [C17H19N3O3F]2·[ZnCl4]·2H2O. Croat. Chem. Acta. 2001, 74, 61-74.
[20] Heinz, G.W.; Marc, S.; Hans, V.T.; Axel, D.; Wolfgang, K. Degradation of Ciprofloxacin by Basidiomycetes and Identification of Metabolites Generated by the Brown Rot Fungus Gloeophyllum striatum. Appl. Environ. Microbiol. 1999, 65, 1556-1563.
[21] Arayne, M.S.; Sultana, N.; Mirza, A.Z., Preparation and spectroscopic characterization of metal complexes of gliquidone. J. Mol. Struct. 2009, 927, 54-59. |